Case Report
| ||||||
Carbamoyl phosphate synthetase 1 deficiency: First report of this rare metabolic disorder in Kingdom of Bahrain with novel mutation | ||||||
Z. Alsahlawi1, E. Aljishi2, M. Aljufairi3, H. Naser4, J. Häberle5 | ||||||
1Pediatric and Metabolic Disease, Medical Genetics Specialist, PO Box 12- Samlmaniya Medical Hospital Hospital, Pediatric Department, Kingdom of Bahrain 2Pediatric and Metabolic Disease Consultant, Pediatric Department, Salmaniya Medical Complex, Manama – Kingdom of Bahrain 3Pediatric Consultant and Neonatologist – Pediatric Department – Salmaniya Medical Complex – Manama – Kingdom of Bahrain 4Pediatric Intern - Pediatric Department – Salmaniya Medical Complex – Manama – Kingdom of Bahrain 5University Children’s Hospital Zurich, Division of Metabolism and Children’s Research Center, 8032 Zurich, Switzerland | ||||||
| ||||||
[HTML Full Text]
[PDF Full Text]
[Print This Article] [Similar article in Pumed] [Similar article in Google Scholar] |
How to cite this article |
Alsahlawi Z, Aljishi E, Aljufairi M, Naser H, Häberle J. Carbamoyl phosphate synthetase 1 deficiency: First report of this rare metabolic disorder in Kingdom of Bahrain with novel mutation. Case Rep Int 2018;7:100044CRINTZA2018. |
ABSTRACT
|
Introduction:
Carbamoyl phosphate synthetase 1 (CPS1) is the first enzyme of the urea cycle, which is the pathway responsible for excess nitrogen detoxification and arginine synthesis. Deficiency of CPS1 will cause severe hyperammonemia often already on the first few days after birth. The majority of patients with CPS1 deficiency have a neonatal presentation with encephalopathy and lethargy due to severe hyperammonemia. These patients usually require intensive care treatment with nitrogen scavenging medication and hemodialysis but despite this, the outcome of these cases is guarded. Case Report: Here we report the first case of CPS1 deficiency in a newborn Bahraini girl who was manifesting on the 3rd day of life with encephalopathy, seizures, and hyperammonemia. She was treated with nitrogen scavenging medication and peritoneal dialysis leading to a decrease of the ammonia level. After starting carglumic acid (Carbaglu), which is the allosteric activator of the urea cycle, the metabolic situation was further improved. Unfortunately, the patient had already sustained severe neurological sequelae and expired after one month. Her diagnosis of a defect in CPS1 was suspected based on the biochemical profile and finally confirmed with the finding of a novel mutation in the CPS1 gene. Conclusion: Hyperammonemia is an acute metabolic emergency and often caused by a UCD that should always be part of the differential diagnosis. We report here the first CPS1 deficiency case, confirmed genetically, in Bahrain with novel mutation. | |
Keywords:
Carbamoyl phosphate synthetase 1 deficiency, Urea cycle defect, Hyperammonemia
|
[HTML Full Text]
[PDF Full Text]
|
Author Contributions
Z. Alsahlawi – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published E. Aljishi – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published M. Aljufairi – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published H. Naser – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published J. Häberle – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published |
Guarantor of Submission
The corresponding author is the guarantor of submission. |
Source of Support
None |
Conflict of Interest
Authors declare no conflict of interest. |
Copyright
© 2018 Z. Alsahlawi et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information. |
ABOUT THE AUTHORS
| |||||||||||||||
| |||||||||||||||
|